NIH reports promising data on remdesivir for aiding COVID-19 recovery
A trial sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a placebo.
Remdesivir is an investigational, broad-spectrum antiviral treatment administered via daily infusion for 10 days.
The randomized, controlled trial, which involved more than 1,000 patients from multiple sites around the world, found that patients who received remdesivir had a 31% faster recovery time, compare with those who received a placebo — 11 days for patients treated with remdesivir, compared with 15 days for those in the control group.
Related News Articles
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…